Restricted accessResearch articleFirst published online 2012-06
Antibodies to the Central Conserved Region of Respiratory Syncytial Virus (RSV) G Protein Block RSV G Protein CX3C-CX3CR1 Binding and Cross-Neutralize RSV A and B Strains
Respiratory syncytial virus (RSV) is a primary cause of severe lower respiratory tract disease in infants, young children, and the elderly worldwide, and despite decades of effort, there remains no safe and effective vaccine. RSV modifies the host immune response during infection by CX3C chemokine mimicry adversely affecting pulmonary leukocyte chemotaxis and CX3CR1+ RSV-specific T-cell responses. In this study we investigated whether immunization of mice with RSV G protein polypeptides from strain A2 could induce antibodies that block G protein–CX3CR1 interactions of both RSV A and B strains. The results show that mice immunized with RSV A2 G polypeptides generate antibodies that block binding of RSV A2 and B1 native G proteins to CX3CR1, and that these antibodies effectively cross-neutralize both A and B strains of RSV. These findings suggest that vaccines that induce RSV G protein–CX3CR1 blocking antibodies may provide a disease intervention strategy in the efforts to develop safe and efficacious RSV vaccines.
Get full access to this article
View all access options for this article.
References
1.
AmanatidouV, SourvinosG, ApostolakisS, TsilimigakiA, SpandidosDA. T280M variation of the CX3C receptor gene is associated with increased risk for severe respiratory syncytial virus bronchiolitis. Pediatric Infect Dis J, 2006; 25:410–414.
ArnoldR, KonigB, WerchauH, KonigW. Respiratory syncytial virus deficient in soluble G protein induced an increased proinflammatory response in human lung epithelial cells. Virology, 2004; 330:384–397.
4.
BeckA, Klinguer-HamourC, BussatMCet al.Peptides as tools and drugs for immunotherapies. J Peptide Sci, 2007; 13:588–602.
5.
BelsheRB, AndersonEL, WalshEE. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J Infect Dis, 1993; 168:1024–1029.
6.
BlountREJr, MorrisJA, SavageRE. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med, 1956; 92:544–549.
BrandtC, PowerUF, Plotnicky-GilquinHet al.Protective immunity against respiratory syncytial virus in early life after murine maternal or neonatal vaccination with the recombinant G fusion protein BBG2Na. J Infect Dis, 1997; 176:884–891.
9.
CanePA. Analysis of linear epitopes recognised by the primary human antibody response to a variable region of the attachment (G) protein of respiratory syncytial virus. J Med Virol, 1997; 51:297–304.
10.
ChanockR, RoizmanB, MyersR. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg, 1957; 66:281–290.
11.
ChanockRM, ParrottRH, ConnorsM, CollinsPL, MurphyBR. Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization. Pediatrics, 1992; 90:137–143.
12.
ConnorsM, CollinsPL, FirestoneCY, MurphyBR. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J Virol, 1991; 65:1634–1637.
13.
CroweJEJr, WilliamsJV. Immunology of viral respiratory tract infection in infancy. Paediatr Respir Rev, 2003; 4:112–119.
14.
de WaalL, PowerUF, YukselSet al.Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge. Vaccine, 2004; 22:915–922.
15.
DurbinAP, KarronRA. Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines. Clin Infect Dis, 2003; 37:1668–1677.
16.
EbbertJO, LimperAH. Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome. Respiration, 2005; 72:263–269.
17.
FalseyAR, HennesseyPA, FormicaMA, CoxC, WalshEE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med, 2005; 352:1749–1759.
18.
FalseyAR, WalshEE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine, 1997; 15:1130–1132.
19.
Garcia-BeatoR, MartinezI, FranciC, RealFX, Garcia-BarrenoB, MeleroJA. Host cell effect upon glycosylation and antigenicity of human respiratory syncytial virus G glycoprotein. Virology, 1996; 221:301–309.
20.
Garcia-BeatoR, MeleroJA. The C-terminal third of human respiratory syncytial virus attachment (G) protein is partially resistant to protease digestion and is glycosylated in a cell-type-specific manner. J Gen Virol, 2000; 81:919–927.
21.
GlezenWP, TaberLH, FrankAL, KaselJA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child, 1986; 140:543–546.
GroothuisJR, KingSJ, HogermanDA, ParadisoPR, SimoesEA. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis, 1998; 177:467–469.
24.
HallCB, WalshEE, LongCE, SchnabelKC. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis, 1991; 163:693–698.
25.
HarcourtJ, AlvarezR, JonesLP, HendersonC, AndersonLJ, TrippRA. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J Immunol, 2006; 176:1600–1608.
26.
HarcourtJL, KarronRA, TrippRA. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis. J Infect Dis, 2004; 190:1936–1940.
27.
HaynesLM, CaidiH, RaduGU, MiaoC, HarcourtJL, TrippRA. Anderson LJ: Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J Infect Dis, 2009; 200:439–447.
28.
HaynesLM, JonesLP, BarskeyA, AndersonLJ, TrippRA. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J Virol, 2003; 77:9831–9844.
29.
HaynesLM, RaduGU, CaidiH, MiaoC, TrippRA, AndersonLJ. Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice. J Virol, 2010; 84:9632–9636.
30.
HendersonFW, CollierAM, ClydeWAJr, DennyFW. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med, 1979; 300:530–534.
31.
HendricksDA, BaradaranK, McIntoshK, PattersonJL. Appearance of a soluble form of the G protein of respiratory syncytial virus in fluids of infected cells. J Gen Virol, 1987; 68,Pt 6:1705–1714.
32.
HendricksDA, McIntoshK, PattersonJL. Further characterization of the soluble form of the G glycoprotein of respiratory syncytial virus. J Virol, 1988; 62:2228–2233.
33.
JohnsonPRJr, OlmstedRA, PrinceGA, MurphyBR, AllingDW, WalshEE, CollinsPL. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol, 1987; 61:3163–3166.
34.
KarronRA, WrightPF, BelsheRCet al.Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis, 2005; 191:1093–1104.
LangedijkJP, de GrootBL, BerendsenHJ, van OirschotJT. Structural homology of the central conserved region of the attachment protein G of respiratory syncytial virus with the fourth subdomain of 55-kDa tumor necrosis factor receptor. Virology, 1998; 243:293–302.
37.
LevineS, KlaiberfrancoR, ParadisoPR. Demonstration that glycoprotein-G is the attachment protein of respiratory syncytial virus. J Gen Virol, 1987; 68:2521–2524.
38.
LiXQ, FuZF, AlvarezR, HendersonC, TrippRA. Respiratory syncytial virus (RSV) infects neuronal cells and processes that innervate the lung by a process involving RSV G protein. J Virol, 2006; 80:537–540.
39.
MartinezI, DopazoJ, MeleroJA. Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants. J Gen Virol, 1997; 78,Pt 10:2419–2429.
40.
MeleroJA, Garcia-BarrenoB, MartinezI, PringleCR, CanePA. Antigenic structure, evolution and immunobiology of human respiratory syncytial virus attachment (G) protein. J Gen Virol, 1997; 78,Pt 10:2411–2418.
41.
MiaoC, RaduGU, CaidiH, TrippRA, AndersonLJ, HaynesLM. Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(abâ€2)2 components mediates reduced pulmonary inflammation in mice. J Gen Virol, 2009; 90:1119–1123.
42.
MuelenaerPM, HendersonFW, HemmingVG, WalshEE, AndersonLJ, PrinceGA, MurphyBR. Group-specific serum antibody-responses in children with primary and recurrent respiratory syncytial virus-infections. J Infect Dis, 1991; 164:15–21.
43.
MufsonMA, OrvellC, RafnarB, NorrbyE. Two distinct subtypes of human respiratory syncytial virus. J Gen Virol, 1985; 66,Pt 10:2111–2124.
44.
MunozFM, PiedraPA, GlezenWP. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine, 2003; 21:3465–3467.
45.
MurataY, LightfootePM, BiearJN, FalseyAR, WalshEE. Humoral response to the central unglycosylated region of the respiratory syncytial virus attachment protein. Vaccine, 2010; 28:6242–6246.
46.
MurphyBR, PrinceGA, WalshEE, KimHW, ParrottRH, HemmingVG, RodriguezWJ, ChanockRM. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol, 1986; 24:197–202.
47.
PalomoC, CanePA, MeleroJA. Evaluation of the antibody specificities of human convalescent-phase sera against the attachment (G) protein of human respiratory syncytial virus: Influence of strain variation and carbohydrate side chains. J Med Virol, 2000; 60:468–474.
48.
PalomoC, Garcia-BarrenoB, PenasC, MeleroJA. The G protein of human respiratory syncytial virus: significance of carbohydrate side-chains and the C-terminal end to its antigenicity. J Gen Virol, 1991; 72,Pt 3:669–675.
49.
PeretTC, HallCB, SchnabelKC, GolubJA, AndersonLJ. Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. J Gen Virol, 1998; 79,Pt 9:2221–2229.
50.
PolackFP, IrustaPM, HoffmanSJet al.The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Proc Natl Acad Sci USA, 2005; 102:8996–9001.
51.
PolackFP, KarronRA. The future of respiratory syncytial virus vaccine development. Pediatr Infect Dis J, 2004; 23:S65–S73.
52.
PolackFP, TengMN, CollinsPLet al.A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med, 2002; 196:859–865.
53.
PowerUF. Respiratory syncytial virus (RSV) vaccines—two steps back for one leap forward. J Clin Virol, 2008; 41:38–44.
54.
PowerUF, NguyenTN, RietveldEet al.Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J Infect Dis, 2001; 184:1456–1460.
55.
PowerUF, Plotnicky-GilquinH, HussTet al.Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology, 1997; 230:155–166.
56.
RobertsSR, LichtensteinD, BallLA, WertzGW. The membrane-associated and secreted forms of the respiratory syncytial virus attachment glycoprotein G are synthesized from alternative initiation codons. J Virol, 1994; 68:4538–4546.
57.
SpandidosDA, AmanatidouV, SourvinosG, ApostolakisS, TsilimigakiA. T280M variation of the CX3C receptor gene is associated with increased risk for severe respiratory syncytial virus bronchiolitis. Pediat Infect Dis J, 2006; 25:410–414.
58.
StottEJ, TaylorG, BallLA, AndersonK, YoungKK, KingAM, WertzBW. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J Virol, 1987; 61:3855–3861.
TrippRA, DakhamaA, JonesLP, BarskeyA, GelfandEW, AndersonLJ. The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P. J Virol, 2003; 77:6580–6584.
61.
TrippRA, JonesL, AndersonLJ. Respiratory syncytial virus G and/or SH glycoproteins modify CC and CXC chemokine mRNA expression in the BALB/c mouse. J Virol, 2000; 43:6227–6229.
62.
TrippRA, JonesLP, HaynesLM, ZhengH, MurphyPM, AndersonLJ. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol, 2001; 2:732–738.
63.
TrippRA, MooreD, JonesL, SullenderW, WinterJ, AndersonLJ. Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J Virol, 1999; 73:7099–7107.
64.
TrippRA, OshanskyCM, BarberJP, CrabtreeJ. Respiratory syncytial virus F and G proteins induce interleukin 1 alpha, CC, and CXC chemokine responses by normal human bronchoepithelial cells. J Infect Dis, 2010; 201:1201–1207.
65.
WertzGW, CollinsPL, HuangY, GruberC, LevineS, BallLA. Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein. Proc Natl Acad Sci USA, 1985; 82:4075–4079.
66.
WertzGW, KriegerM, BallLA. Structure and cell surface maturation of the attachment glycoprotein of human respiratory syncytial virus in a cell line deficient in O glycosylation. J Virol, 1989; 63:4767–4776.
67.
WrightPF, KarronRA, BelsheRBet al.Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis, 2000; 182:1331–1342.
68.
ZhangW, ChoiY, HaynesLM, HarcourtJL, AndersonLJ, JonesLP, TrippRA. Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J Virol, 2010; 84:1148–1157.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
